Blog

Free access to PharmScreen for COVID-19 research

Free access to PharmScreen for COVID-19 research
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 has spread to all countries without exception, affecting not only risk-population but also young people and healthy individuals. At Pharmacelera we want to join the different public and private initiatives to find a treatment that can stop the expansion of the virus. To do so,…
Read more

Pharmacelera: 2019 Summary

Pharmacelera: 2019 Summary
2019 was an exciting year for Pharmacelera and we look forward to 2020 with energy and commitment. Stay tuned for updates in forthcoming months! Let's have a look to the 2019 summary! Collaborations and Partnerships This year has been very productive for us. For example, we have started a new collaboration with a top 10…
Read more

Measuring Virtual Screening Accuracy

Measuring Virtual Screening Accuracy
Virtual Screening (VS) is a core in-silico technology in medicinal and computational chemistry. Several tools have been developed to exploit protein structures or collections of compounds to provide a quick and economical method for the discovery of novel active compounds. Hence, the comparative evaluation of VS algorithms becomes a fundamental exercise to assess the applicability…
Read more

IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications

IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications
Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block the cohesin complex, with applications in several difficult-to-treat cancers, such as myeloid leukemia, glioblastomas, Ewing sarcomas, colon cancer and bladder cancer. The cell cycle research group of the Bellvitge Biomedical Research Institute (IDIBELL),…
Read more